A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs MVA BN YF (Primary) ; Montanide ISA-720; Smallpox vaccine; Yellow fever vaccine
- Indications Yellow fever
- Focus Adverse reactions
- 13 Jul 2017 Planned primary completion date changed from 31 Mar 2017 to 25 Jul 2017.
- 13 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2016 New trial record